IBERIA PHARMACEUTICALS INDIA LIMITED

rhp filedRefreshing

Source: SEBI

Issue price

—

Issue size

—

Fresh issue

—

Offer for sale

—

Bull / base / bear

What would have to hold for each case — not a price target or a projected figure. CapitSignal does not forecast where this stock trades.

The company successfully establishes its own manufacturing facility on schedule.
The company is proposing to set up manufacturing facilities, which could enhance operational efficiency and reduce reliance on third-party manufacturers.
The Indian pharmaceutical market continues to grow at a CAGR of 13-15%.
The market is projected to reach about USD 110-120 billion by FY30, driven by increased health insurance penetration and rising chronic disease prevalence.

The company maintains its current revenue growth trajectory.
Revenue from operations for Fiscal 2026 was ₹9,653.70 lakhs, showing a consistent increase from previous years.
The company continues to derive a significant portion of its revenue from its top brands.
The company derived 83.96% of its revenue from operations in Fiscal 2026 from its top 2 brands, indicating strong brand loyalty.

The company faces disruptions in its relationships with brand owners and suppliers.
The company is dependent on relationships with brand owners and suppliers for exclusive distribution rights, and any disruption could adversely affect its business.
Regulatory compliance issues lead to penalties or operational disruptions.
The company has experienced non-compliance issues in the past, which could lead to penalties and affect its financial health.